Validity of clinical associations of biomarkers in translational research studies: The case of systemic autoimmune diseases

Arthritis Research and Therapy

Volumn 12, Issue 5, 2010, Pages

  Tektonidou, Maria G ^a,b   Ward, Michael M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; ENZYME;

ANCA ASSOCIATED VASCULITIS; ARTICLE; AUTOIMMUNE DISEASE; DISEASE ACTIVITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE EXPRESSION PROFILING; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MYOSITIS; PROGNOSIS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSLATIONAL RESEARCH; VALIDITY; FEMALE; MALE; METHODOLOGY; STANDARD; VALIDATION STUDY;

AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; RESEARCH DESIGN; TRANSLATIONAL RESEARCH;

EID: 77957144828     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3143     Document Type: Article

References (25)

1. Biomarkers Definition Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. 10.1067/mcp.2001.113989, 11240971, Biomarkers Definition Working Group.
2. Paul M. Translational investigators: life sciences' application engineers. Nat Biotechnol 2007, 25:817-818. 10.1038/nbt0707-817, 17621304.
3. Ozdemir V, Williams-Jones B, Cooper DM, Someya T, Godard B. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 2007, 8:177-185. 10.2217/14622416.8.2.177, 17286540.
4. Muñoz A, Gange SJ. Methodological issues for biomarkers and intermediate outcomes in cohort studies. Epidemiol Rev 1998, 20:29-42.
5. Ward MM. Evaluative laboratory testing: assessing tests that assess disease activity. Arthritis Rheum 1995, 38:1555-1563. 10.1002/art.1780381106, 7488275.
6. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus, I: general overview of biomarkers and their applicability. Arthritis Rheum 2004, 50:1709-1720. 10.1002/art.20344, 15188346.
7. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus, II: markers of disease activity. Arthritis Rheum 2004, 50:2048-2065. 10.1002/art.20345, 15248202.
8. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
9. Kehlen A, Thiele K, Riemann D, Langner J. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol 2002, 127:539-546.
10. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R, Rader DJ, Lazar MA, Reilly MP. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007, 49:442-449. 10.1016/j.jacc.2006.09.034, 17258089.
11. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978, 299:926-930. 10.1056/NEJM197810262991705, 692598.
12. Feng X, Wu H, Grossman J, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:2951-2962. 10.1002/art.22044, 16947629.
13. Liang MH, Simard JF, Costenbader K, Dore BT, Ward M, Fortin PR, Illei GG, Manzi S, Mittleman B, Buyon J, Gupta S, Abrahamowicz M. Methodologic issues in the validation of putative biomarkers and surrogate end points in treatment evaluation for systemic lupus erythematosus. Endocr Metab Immune Disord Drug Targets 2009, 9:108-112. 10.2174/187153009787582388, 19275685.
14. Liu CC, Ahearn JM. The search for lupus biomarkers. Best Pract Res Clin Rheumatol 2009, 23:507-523. 10.1016/j.berh.2009.01.008, 2727983, 19591781.
15. Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O. The need for prognosticators in rheumatoid arthritis: biological and clinical markers: where are we now?. Arthritis Res Ther 2008, 10:208. 10.1186/ar2418, 2483438, 18557991.
16. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, Brown PO. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003, 100:1896-1901. 10.1073/pnas.252784499, 149930, 12578971.
17. Eady JJ, Wortley GM, Wormstone YM, Hughes JC, Astley SB, Foxall RJ, Doleman JF, Elliott RM. Variation in gene expression profiles of peripheral blood mononuclear cells from healthy volunteers. Physiol Genomics 2005, 22:402-411. 10.1152/physiolgenomics.00080.2005, 16014386.
18. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serological features and active disease. Arthritis Rheum 2005, 52:1491-1503. 10.1002/art.21031, 15880830.
19. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13:59-68. 10.2119/2006-00085.Baechler, 1869622, 17515957.
20. Sawyers CL. The cancer biomarker problem. Nature 2008, 452:548-552. 10.1038/nature06913, 18385728.
21. Simon R. Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 2008, 44:2707-2713. 10.1016/j.ejca.2008.09.009, 2646591, 18977655.
22. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008, 14:5967-5976. 10.1158/1078-0432.CCR-07-4535, 2744124, 18829475.
23. Floyd E, McShane TM. Development and use of biomarkers in oncology drug development. Toxicol Pathol 2004, 32(suppl 1):106-115. 10.1080/01926230490425021, 15209410.
24. Clerico A, Vittorini S, Passino C, Emdin M. New and emerging biomarkers of heart failure. Crit Rev Clin Lab Sci 2009, 46:107-128. 10.1080/10408360902722342, 19514904.
25. Andreassi MG, Gastaldelli A, Clerico A, Salvadori PA, Sicari R, Picano E. Imaging and laboratory biomarkers in cardiovascular disease. Curr Pharm Des 2009, 15:1131-1141. 10.2174/138161209787846937, 19355954.